# name
Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials

# metadata.dc.description.abstract[].value
Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)

# metadata.dc.publisher[].value
Cortex - Publicacoes Tecnicas e Cientificas

# metadata.dc.relation.ispartof[].value
Revista Portuguesa de Diabetes, 2019, vol. 14, num. 4, p. 141-150

# metadata.dc.rights[].value
cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019

# metadata.dc.source[].value
Articles publicats en revistes (Economia)

# metadata.dc.title[].value
Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials